Wuxi Biologics (Cayman) (HK:2269) has released an update.
Wuxi Biologics (Cayman) Inc. has reported a 1% revenue growth in the first half of 2024 compared to 2023, despite a drop in net profit by 23.9% and a decline in earnings per share by 32.7%. The company, however, demonstrated resilience and growth potential with an increase in integrated projects to 742, indicating sustained business development and a robust CRDMO platform strategy. No interim dividend was declared for the six-month period ending June 30, 2024.
For further insights into HK:2269 stock, check out TipRanks’ Stock Analysis page.
